Core Insights - Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic candidates to guide T cells in disease control [1][8] - The company is undergoing a strategic restructuring to prioritize its SNAP-TI platform for autoimmune diseases and extend its cash runway to early 2027 [5][6] Strategic Business Focus and Restructuring - The company will prioritize the development of VTP-1000 for celiac disease, with Phase 1 data expected in mid-2025 [5][6] - Further clinical development of VTP-300 for chronic hepatitis B is postponed until a partner is identified [5][6] - A significant workforce reduction of approximately 65% is planned, along with the closure of the U.K. site, focusing future operations in Germantown, Maryland [5][6] Financial Update - Cash, cash equivalents, and restricted cash are projected to be $112 million as of December 31, 2024, which is expected to fund operations until early 2027 [6][7] - The company aims to streamline operating costs as part of its restructuring efforts [6] Anticipated 2025 Corporate Milestones - Results from the Phase 1 PCA001 clinical trial for VTP-850 in prostate cancer are expected in Q2 2025 [4][5] - Announcement of single ascending dose data from the AVALON Phase 1 trial for VTP-1000 in celiac disease is anticipated in mid-2025 [6] - Results from the Phase 2b HBV003 clinical trial for VTP-300 are expected in Q2 2025 [6]
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update